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SEK. ConClusions: Given a willingness-to-pay threshold of 600,000 SEK/QALY, 
posaconazole is likely to be cost-effective for preventing IFIs in GVHD-patients 
compared to fluconazole.
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Israeli ministry of health guidelines for antenatal screening recommend HIV test-
ing only in women belonging to high risk groups. This policy resulted in the last 
10 years in an annual average of two infected children from unidentified Israeli 
women. objeCtives: To evaluate an alternative strategy of universal screen-
ing using a cost utility analysis. Methods: A budget impact analysis was first 
conducted to evaluate the cost of introducing universal screening using a payer 
perspective. Following, a cost-utility analysis (CUA) was carried out to evaluate 
long term effects of such strategy, compared with current policy. The model was 
comprised of two steps: a decision tree simulating the period from pregnancy 
to delivery and a successive Markov model simulating life expectancy of the 
newborn. Screening test sensitivity and specificity were regarded as 99.94% and 
99.5% respectively. Probabilities for having HIV for the low and high-risk popula-
tions were based on experts’ opinion. They were then adjusted to allow model 
calibration to reflect real-life finding as presented above. The cost of the screen-
ing test was US$ 5.5. Other costs included physician visits, viral load and blood 
tests, CD4 counts, and medications. QALY weights were 0.83 for HIV and 0.7 for 
AIDS. Results: Probabilities for having HIV for the low and high-risk populations 
were 0.0215% and 1% respectively. The incremental cost of the universal screening 
over current policy for an annual cohort of 166,000 Israeli pregnant women was 
US$1 million, reflecting a cost of $500,000 per a case of an HIV+ baby avoided. For 
this cohort, an incremental 18 QALYS were projected over a 90 year time hori-
zon with an incremental cost-effectiveness ratio of US$ -30,000. ConClusions: 
Universal Antenatal HIV screening should be implemented in Israel. The current 
policy of screening identified high-risk women is both less effective and more 
costly.
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objeCtives: In France, rilpivirine is reimbursed for HIV-1-infected treatment-
naïve patients with VL≤ 100,000 copies/mL for whom the use of efavirenz is not 
appropriate. This analysis aims to compare costs and outcomes of rilpivirine vs. 
other third antiretroviral (ARVs) agent recommended in France (in addition to two 
NRTIS). Methods: A cohort-based Markov model with four therapy lines and six 
health states based on CD4+ cell-count ranges was developed based on 1-year 
cycle and a 5-year time horizon. First-line efficacy data at 48 and 96 weeks was 
first assumed to be similar across treatments, and subsequently set to statisti-
cally significantly different (SSD) values from phase-III trial analyses of patients 
with VL≤ 100,000 copies/mL. Costs of first-line treatments were obtained from the 
French National Formulary. Costs associated with subsequent treatments and 
CD4+ health states were derived from a French cost-effectiveness analysis. Other 
clinical inputs, HIV-related mortality rates and utility were derived from inter-
national publications. Outcomes and costs were discounted at 4%. Robustness 
of results was assessed using sensitivity analyses (e.g. using efficacy values 
no SSD). Results: All phase-III trials (i.e. ECHO/THRIVE, STARTMRK, CASTLE, 
ARTEMIS, KLEAN, GEMINI, 2NN) demonstrated a non-inferior antiviral efficacy 
between arms. In patients with VL≤ 100,000 copies/mL, response rates were avail-
able for rilpivirine (1-year: 90,2%; 2-year: 84,0%), ritonavir-boosted (/r) darunavir 
(1-year: 79,5%; 2-year: 76,1%), lopinavir/r (1-year: 84,5%; 2-year: 75,2%), atazanavir/r 
(1-year: 82%; 2-year: 75%), fosamprenavir/r (1-year: 67%) and raltegravir (1-year: 
93%). CD4+ cell count changes per mm3 were available for atazanavir/r (1-year: 
+179; 2-year: +243), lopinavir/r (1-year: +194; 2-year: +267), rilpivirine (1-year: +185) 
and raltegravir (1-year: +180). Rilpivirine was the less expensive option in the cost-
minimisation analyses and dominated all treatments in the cost-effectiveness 
analyses when considering SSD efficacy values. ConClusions: The analysis pro-
vided health economic results for HIV-1-infected treatment-naïve patients with 
VL≤ 100,000 copies/mL favoring rilpivirine over all other ARVs analysed.
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objeCtives: To assess the cost-effectiveness of telaprevir (TVR) added to peginter-
feron and ribavirin (PR) therapy in treatment naive (TN) and experienced (TE) 
genotype 1 chronic HCV patients in Poland. Methods: Analysis was based on 
a previously validated Markov model, describing the progression of the disease 
over a lifetime, adapted to population characteristics specific to Poland and cost 
parameters obtained via questionnaire studies completed by clinical practition-
ers. The model comprises the following health states: mild CHC without/with 
SVR (remission), moderate CHC without/with SVR, cirrhosis without/with SVR, 
antiviral therapy, decompensated cirrhosis, HCC, liver transplantation, post-liver 
transplant, CHC related death. The following treatment strategies were considered: 
PEG++ RBV therapy for 48 weeks; TVR for 12 weeks with PEG+RBV (response-guided 
therapy in TN and 48 weeks in TE patients). A cost-utility analysis was conducted 
goal of this study was to perform economic evaluation of maraviroc compared with 
other new antiretroviral agents, such as raltegravir, darunavir and enfuvirtide for 
treatment-experience patients with HIV infection in Russia. Methods: Indirect 
comparison was performed to assess the relative clinical efficacy and safety of 
compared drugs, all in combination with optimized background therapy (OBT). 
A mathematical model was created in Microsoft Excel software to estimate the 
direct medical costs of: compared drugs, an average OBT regimen and routine 
outpatient follow-up (including visits to specialists and diagnostic tests). Drug 
and medical services cost calculations were based on registered prices from the 
list of vital and essential drugs and financial standards of regional program of 
national guarantees for the provision of free medical care to Russian citizens in 
Moscow in 2012, respectively. The obtained results were tested in sensitivity analy-
sis. Results: According to indirect comparison results, there were no statistically 
significant differences between maraviroc, raltegravir, darunavir and enfuvirtide 
neither by the undetectable HIV RNA level nor CD4(+) cell-count changes. The rate 
of adverse events was comparable (except enfuvirtide that has more injection-site 
reactions). Maraviroc-containing regimen compared with raltegravir-, darunavir- 
and enfuvirtide-containing regimen is associated with reduced costs and saves 
an average 177 764.16 rub (€ 4 209.94), 59 929.92 rub (€ 1 419.30) and 462 295.92 rub 
(€ 10 948.42) per 48 weeks of therapy, and 340 714.64 rub (€ 8 069.05) and 114 865.68 
rub (€ 2 720.33) and 886 067.18 rub (€ 20 984.47) per 96 weeks of therapy per patient, 
respectively. Results were robust in one-way sensitivity analyses. ConClusions: 
The analysis showed that maraviroc compared with darunavir, raltegravir and 
enfuvirtide is a cost-saving treatment option for CCR5 tropic treatment-experi-
enced patients in Russia.
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objeCtives: The addition of boceprevir (BOC) to peginterferon–ribavirin (PR) 
resulted in significantly higher rates of sustained virologic response in naive or 
pretreated patients with the chronic hepatitis C virus (HCV) genotype 1 infection, as 
compared with PR alone. The objective is to project the long-term clinical benefits 
and estimate the cost-effectiveness of the treatment strategies recommended in 
the BOC label compared with PR alone. Methods: A Markov model was created 
to estimate the expected costs and quality adjusted life-years (QALYs) associated 
with the BOC tritherapy and PR. The model simulates the treatment regimens and 
the natural history of the chronic HCV to project the lifetime cumulative incidence 
of advanced liver-related diseases (decompensated cirrhosis (DC), hepatocellular 
carcinoma (HCC)) and liver transplant. Series of 30 cohorts representing all com-
binations of pre-specified patient characteristics progress through the model. The 
baseline characteristics used to define the cohorts are: naive/pretreated, age, gender, 
baseline fibrosis score and race cohort for the treatment naive population only. 
Separate analyses were run for naive and pretreated patients. The distribution of 
baseline fibrosis score for each analysis was based on the subjects enrolled in the 
clinical trials; the average age and distribution of race cohort were based on French 
observational study (F. Roudot Thoraval, ADEQUATION, AFEF 2009). The comparator 
was PR (48 weeks). Results: The model predicted relative reductions in patients 
treated with BOC vs PR alone: 33% and 32% in DC/HCC in naive patients and also 
46% and 53% in DC/HCC in pretreated patients. The ICER of BOC-based therapy 
compared with PR were 15,681€ /QALY for naive patients and 10,563€ /QALY for pre-
treated patients. ConClusions: Compared with PR, boceprevir-based treatment is 
projected to substantially reduce the burden of liver complications associated with 
the chronic hepatitis C virus genotype 1 and is highly cost-effective if a threshold 
of 50,000€ /QALY is assumed.
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objeCtives: In allogeneic transplant (allo-SCT) recipients with graft-versus-host 
disease (GVHD) the risk of contracting an invasive fungal infection (IFI) is high and 
antifungal prophylaxis to prevent IFIs is routinely given. Fluconazole, has been 
standard antifungal prophylaxis in GVHD-patients in Sweden. Recently many 
Swedish centers have switched from fluconazole, which lacks efficacy against 
Aspergillus, to posaconazole, for the prevention of IFIs in GVHD-patients receiving 
moderate to high doses of glucocorticoids. Although, the superior efficacy of posa-
conazole vs. fluconazole in preventing IFIs have been demonstrated in this clinical 
setting, the cost-effectiveness of posaconazole vs. fluconazole for GVHD-patients in 
Sweden has not been established. The aim of this analysis is to estimate the cost-
effectiveness of posacoanzole vs. fluconazole prophylaxis in allo-SCT recipients 
with severe GVHD receiving immunosuppressive therapy in Sweden. Methods: 
A decision-analytic model was used to determine life-time outcomes of patients 
with GVHD at high risk of contracting IFIs. The model outcomes were quality 
adjusted life years (QALYs), costs associated with IFI-prophylaxis and treatment 
of IFIs and the incremental cost-utility ratio. The efficacy data were gathered from 
a clinical trial comparing posaconazole with fluconazole prophylaxis in patients 
with GVHD. The resource use for treatment of IFIs was gathered by expert opin-
ion. Utility, mortality and unit costs were gathered from the literature. To assess 
the uncertainty of the modeled outcomes a probabilistic sensitivity analysis (PSA) 
was developed. Results: The incremental cost-utility ratio of posaconazole vs. 
fluconazole for the prevention of IFI in GVHD-patients in Sweden was 541,628 SEK/
QALY. The PSA showed a 56.4% probability for a cost per QALY less than 600,000 
